These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7147857)

  • 1. Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis.
    Valbonesi M; Garelli S; Zerbi D; Forlani G; Cornelio F; Pelucchetti D
    Vox Sang; 1982; 43(3):142-6. PubMed ID: 7147857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma exchange and immunosuppressive drug treatment in myasthenia gravis: no evidence for synergy.
    Hawkey CJ; Newsom-Davis J; Vincent A
    J Neurol Neurosurg Psychiatry; 1981 Jun; 44(6):469-75. PubMed ID: 7276959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients.
    Dau PC
    Ann N Y Acad Sci; 1981; 377():700-8. PubMed ID: 6951494
    [No Abstract]   [Full Text] [Related]  

  • 4. Lymphocytapheresis in combination with immunosuppressive drugs for refractory myasthenia gravis: two-color flow cytometric analysis of changes in peripheral blood lymphocyte subsets.
    Furutama D; Nakajima H; Shinoda K; Makino S; Ohsawa N
    Eur Neurol; 1995; 35(5):270-5. PubMed ID: 8542915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis.
    Behan PO; Shakir RA; Simpson JA; Burnett AK; Allan TL; Haase G
    Lancet; 1979 Sep; 2(8140):438-40. PubMed ID: 89500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenia gravis treatment: twelve years experience on 110 patients.
    Valli G; Jann S; Premoselli S; Scarlato G
    Ital J Neurol Sci; 1987 Dec; 8(6):593-601. PubMed ID: 3429218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies.
    Lin PT; Martin BA; Weinacker AB; So YT
    Muscle Nerve; 2006 Mar; 33(3):433-5. PubMed ID: 16116645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive treatment for juvenile myasthenia gravis.
    Badurska B; Ryniewicz B; Strugalska H
    Eur J Pediatr; 1992 Mar; 151(3):215-7. PubMed ID: 1601015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of myasthenia gravis with plasmapheresis (author's transl)].
    Reuther P; Wiebecke D; Hertel G; Böske A; Mertens HG
    Dtsch Med Wochenschr; 1979 Dec; 104(51):1806-10. PubMed ID: 520174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma exchange for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2002; 2002(4):CD002275. PubMed ID: 12519572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmapheresis combined with lymphocytapheresis and cytotoxic drugs as a therapeutic modality in neuroimmunological diseases.
    Valbonesi M; Montani F; Florio G; Zerbi D; Beltramelli A
    Ital J Neurol Sci; 1984 Mar; 5(1):35-40. PubMed ID: 6329999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission of myasthenia gravis following plasma-exchange.
    Pinching AJ; Peters DK
    Lancet; 1976 Dec; 2(8000):1373-6. PubMed ID: 63848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmapheresis in myasthenia gravis.
    Dau PC
    Prog Clin Biol Res; 1982; 88():265-85. PubMed ID: 7100216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis.
    Nagappa M; Netravathi M; Taly AB; Sinha S; Bindu PS; Mahadevan A
    J Clin Neurosci; 2014 Nov; 21(11):1909-14. PubMed ID: 25043165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive drug therapy in myasthenia gravis.
    Niakan E; Harati Y; Rolak LA
    Arch Neurol; 1986 Feb; 43(2):155-6. PubMed ID: 3947257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmapheresis therapy in myasthenia gravis.
    Dau PC
    Muscle Nerve; 1980; 3(6):468-82. PubMed ID: 7453714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Favorable results of plasmapheresis in severe myasthenia gravis].
    Blom RJ; Kuks JB; Westerterp-Maas A; Oosterhuis HJ
    Ned Tijdschr Geneeskd; 1997 Feb; 141(8):381-4. PubMed ID: 9157298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
    Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
    N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of plasma exchange in treatment of myasthenia gravis.
    Dau PC
    Prog Clin Biol Res; 1982; 106():143-56. PubMed ID: 7178136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.